SERA Prognostics General Counsel Jackson Benjamin Sells 965 Shares at $1.48/Share.

Sera Prognostics, Inc. [SERA] announces that General Counsel Jackson Benjamin has sold 965 shares at $1.48 per share on June 10, 2025.

Sera Prognostics, Inc. [SERA], a health diagnostic company specializing in biomarker tests for early pregnancy complications, has reported that General Counsel Jackson Benjamin sold 965 shares at $1.48 per share on June 10, 2025. This transaction, filed with the SEC, provides insights into the company's insider trading activities and potential sentiment among key stakeholders.

The sale of 965 shares by Benjamin at an average price of $1.48 per share represents a significant decrease in his direct ownership in the company. This move comes amidst a series of recent insider transactions and analyst ratings that have shaped the market's perception of Sera Prognostics' stock.

Sera Prognostics, Inc. is a NASDAQ-listed company that focuses on improving maternal and neonatal health through innovative biomarker tests. The company's flagship product, the PreTRM test, aims to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies.

The company has been active in investor relations, participating in various conferences and presenting its latest achievements. On May 21, 2025, Sera Prognostics presented at the RBC Global Healthcare Conference, providing updates on its operations and recent developments.

The insider transaction by Benjamin is part of a broader trend of institutional and insider activity. In recent months, several directors and executives have been granted or sold shares, indicating varying levels of confidence in the company's future prospects. Analyst ratings have also fluctuated, with Citigroup downgrading the stock from a "Buy" to "Neutral" with a new price target of $4.00 on March 30, 2022.

Investors should closely monitor these developments, as insider trading can often reflect the true sentiment of key stakeholders. The recent sale by Benjamin, along with other insider transactions and analyst ratings, provides valuable insights into the current market perception of Sera Prognostics.

References:
[1] https://quantisnow.com/company/SERA